drugset / Trial / NCT04685915
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
NaSingle-groupOpen-labelTreatment
Summary
This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib or acalabrutinib in select participants who have been on ibrutinib or acalabrutinib for at least six months for relapsed/refractory chronic lymphocytic leukemia (CLL). The names of the study drugs involved in this study are: * Copanlisib * Ibrutinib * Acalabrutinib
Timeline
- Start
- 2021-02-18
- Primary completion
- 2023-03-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |
| Background | Acalabrutinib | Small molecule | — | Oral |
| Background | Ibrutinib | Small molecule | — | Oral |